leisure time -WSS

leisure time

author：Wikipedia 2025-10-04 11:57:20 - browse：1459

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Boston competes with Raleigh

explore

entertainment

Wikipedia

WSS

Boston competes with Raleigh

New clues to why women have higher risk of autoimmune disorders

Medicare drug price negotiation legal challenge met with skepticism

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

SCOTUS to consider access to abortion pill mifepristone

Americans' trust in science, scientist continues decline: Report

knowledge

leisure time

explore

Tori Bowie and the unacceptable rates of Black maternal death

Reconstructing family trees of blood cells may help predict disease

Medicare proposal to cover medical devices draws a mixed reaction

Teach medical students about patients with intellectual disabilities

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New clues to why women have higher risk of autoimmune disorders

BioMarin wins approval for gene therapy to treat hemophilia A

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Peter Hotez and the public health issue of online harassment

Teach medical students about patients with intellectual disabilities

explore

Roche to buy Carmot Therapeutics, developer of obesity drugs

Vertex non

FDA approves world's first CRISPR

Humana’s losses in Medicare Advantage tank its stock

Teach medical students about patients with intellectual disabilities

Venture capital firm's plans to take over Akron hospital face hurdles

explore

entertainment

Wikipedia

entertainment